...
首页> 外文期刊>Critical care medicine >The largest ever trial demonstrating effectiveness of intensive care unit delirium prophylaxis-We must know more!
【24h】

The largest ever trial demonstrating effectiveness of intensive care unit delirium prophylaxis-We must know more!

机译:证明重症监护病房预防ir妄的有效性的最大规模试验-我们必须了解更多!

获取原文
获取原文并翻译 | 示例
           

摘要

To the Editor:The 457-patient, two-center, randomized placebo-controlled trial of low-dose haloperidol prophylaxis in the intensive care unit (ICU) patients of Wang et al in the March 2012 issue of Critical Care Medicine (1), in which haloperidol significantly decreased the incidence and duration of delirium and reduced ICU length of stay in postoperative ICU patients, is the largest ever trial demonstrating the effectiveness of delirium prophylaxis in the ICU. Aside from trials comparing sedative agents, only one other strategy, early physical and occupational therapy (2), has been shown to reduce ICU delirium. The results have such important and immediate practice implications that the manuscript cannot pass without comment. Further information about the study would strengthen arguments to adopt this practice.
机译:致编辑:2012年3月出版的《重症监护医学》(Critical Care Medicine),Wang等人在重症监护病房(ICU)患者中进行的低剂量氟哌啶醇预防的457患者,两中心,随机安慰剂对照试验(1),氟哌啶醇可显着降低术后ICU患者的ir妄发生率和持续时间,缩短ICU住院时间,这是有史以来规模最大的一项试验,证明了预防ICU the妄的有效性。除了比较镇静剂的试验外,仅另一种策略,即早期物理和职业治疗(2),已显示出可以减少ICU ir妄。结果具有重要而直接的实践意义,手稿若无评论就无法通过。有关该研究的更多信息将加强采用这种做法的论点。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号